About Certara
Certara is a company based in Princeton (United States) founded in 2008 was acquired by EQT in July 2017. The company has 1,550 employees as of December 31, 2024. Certara has completed 10 acquisitions, including Analytica Laser, Applied BioMath and BaseCase. Certara offers products and services including Phoenix™, Pinnacle 21, Simcyp™, and GlobalSubmit™. Certara operates in a competitive market with competitors including Insitro, HotSpot Therapeutics, TOLREMO therapeutics, Inpharmatica and CytoReason, among others.
- Headquarter Princeton, United States
- Employees 1550 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Certara, Inc.
-
Annual Revenue
$385.15 M (USD)8.7as on Dec 31, 2024
-
Net Profit
-$12.05 M (USD)78.23as on Dec 31, 2024
-
EBITDA
$86.85 M (USD)23.85as on Dec 31, 2024
-
Latest Funding Round
Not available
-
Investors
Golub Capital
& 5 more
-
Employee Count
1550
as on Dec 31, 2024
-
Investments & Acquisitions
Analytica Laser
& 9 more
- Acquired by
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Certara
Certara is a publicly listed company on the NASDAQ with ticker symbol CERT in USA, operating in the Technology services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Certara
Certara offers a comprehensive portfolio of products and services, including Phoenix™, Pinnacle 21, Simcyp™, and GlobalSubmit™.
Tool for PK, PD, and toxicokinetic analysis and modeling
Platform for data standardization and validation in drug development
System for predicting drug behavior in diverse populations
Solution for publishing and transmitting eCTD submissions
People of Certara
Unlock access to complete
Unlock access to complete
Funding Insights of Certara
Investors in Certara
Certara has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Golub Capital, EQT and Mubadala.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity investments target specialty industrials and healthcare sectors.
|
Locked | Locked | Locked | |
|
EQT is recognized as a global investment organization focused on value creation.
|
Locked | Locked | Locked | |
|
The U.S. Food and Drug Administration is tasked with regulating food, drugs, and medical products.
|
Locked | Locked | Locked |
Investor details for Certara
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Certara
Certara has strategically engaged in corporate development activities, having acquired 10 companies. Notable acquisitions include Analytica Laser, Applied BioMath and BaseCase.
Investment portfolio details for Certara
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Deep learning platform is provided for life sciences market research.
|
Locked | Locked | 2016 | Locked | |
|
Systems biology and pharmacology modeling services to aid drug discovery and development
|
Locked | Locked | 2013 | Locked | |
|
Clinical pharmacology consulting services are provided for drug development.
|
Locked | Locked | 2012 | Locked |
Complete acquisition details for Certara
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Certara
Detailed financials for Certara
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Certara Comparisons
Peer comparison for Certara
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Certara
Certara operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, HotSpot Therapeutics, TOLREMO therapeutics, Inpharmatica and CytoReason, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Developer of a platform for protein function analysis
|
|
| Locked | Locked | Locked |
Anti-cancer small molecules are developed to target drug resistance pathways.
|
|
| Locked | Locked | Locked |
Developer of predictive informatics based platform for drug discovery
|
|
| Locked | Locked | Locked |
Immune system-based drugs are discovered via biological data analytics.
|
Detailed competitors of Certara
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Certara
Complete news archive for Certara
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Certara
Certara was founded in 2008 and raised its 1st funding round 5 years after it was founded.
Certara is headquartered in Princeton, United States. It is registered at Princeton, New Jersey, United States.
William Feehery is the current CEO of Certara.
As of Dec 31, 2024, the latest employee count at Certara is 1,550.
Annual revenue of Certara is $385.15M as on Dec 31, 2024.
Certara was founded in 2008 and is headquartered in Princeton, United States. Operations focus on the biosimulation sector, where software solutions for molecular modeling, pharmacokinetic and pharmacodynamic simulations, clinical trial modeling, and scientific informatics are developed. Drug development consulting and medical writing services are also delivered to support pharmaceutical research and regulatory needs.
Certara's top competitors include Insitro, HotSpot Therapeutics and GRO Biosciences.
Certara offers Phoenix™, Pinnacle 21, Simcyp™, and GlobalSubmit™.
Yes, Certara is publicly traded on NASDAQ under the ticker symbol CERT.
Certara has made 10 acquisitions, including Analytica Laser, Applied BioMath, and BaseCase.
Certara has 6 investors. Key investors include Golub Capital, EQT, Mubadala, Arsenal Capital Partners, and European Union.
The ticker symbol of Certara is CERT on NASDAQ.